Publications by authors named "Cath Eberlein"

Claim this Profile
T
The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer.
Valentina Cutano, Ming Li Chia, Eleanor M Wigmore, Lorna Hopcroft, Stuart C Williamson, Cath Eberlein

NPJ Breast Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours.
Carlos Fernandez-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou

Clin Pharmacokinet· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance.
Shauna McClelland, Pamela J Maxwell, Cristina Branco, Simon T Barry, Cath Eberlein

Cancers (Basel)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Cath Eberlein, Stuart C Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss

Br J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole.
Claire Miller, Roberto Sommavilla, Simon T Barry, Cath Eberlein, Thomas Morris

Clin Pharmacol Drug Dev· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, Susana Ros, Cath Eberlein

NPJ Breast Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, Susana Ros, Cath Eberlein

NPJ Breast Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, Susana Ros, Cath Eberlein

NPJ Breast Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Shanade Dunn, Cath Eberlein, Jason Yu, Albert Gris-Oliver, Swee Hoe Ong

Oncogene· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mixed micelles of lipoic acid-chitosan-poly(ethylene glycol) and distearoylphosphatidylethanolamine-poly(ethylene glycol) for tumor delivery.
Zeeneh Elsaid, Kevin M G Taylor, Sanyogitta Puri, Cath A Eberlein, Khuloud Al-Jamal

Eur J Pharm Sci· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma.
Matthew J Martin, Cath Eberlein, Molly Taylor, Susan Ashton, David Robinson

Oncotarget· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.
Edward J Hennessy, Claudio Chuaqui, Susan Ashton, Nicola Colclough, Darren A E Cross, Cath Eberlein

ACS Med Chem Lett· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.
Michael G Rolf, Jon O Curwen, Margaret Veldman-Jones, Cath Eberlein, Jianyan Wang

Pharmacol Res Perspect· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Darren A E Cross, Susan E Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A Nebhan

Cancer Discov· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Richard A Ward, Mark J Anderton, Susan Ashton, Paul A Bethel, Matthew Box, Cath Eberlein

J Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
David W Jenkins, Sarah Ross, Margaret Veldman-Jones, Ian N Foltz, Brandon C Clavette, Cath Eberlein

Mol Cancer Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.
Jane Kendrew, Cath Eberlein, Brad Hedberg, Karen McDaid, Neil R Smith

Mol Cancer Ther· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
Sandra R Brave, Cath Eberlein, Masabumi Shibuya, Stephen R Wedge, Simon T Barry

Angiogenesis· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis